AbbVie Inc. [NYSE: ABBV] traded at a high on 08/29/23, posting a 0.11 gain after which it closed the day’ session at $147.59. The company report on August 28, 2023 at 8:45 AM that AbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative Colitis.
Submissions are supported by two Phase 3 clinical trials demonstrating risankizumab achieved the primary endpoint of clinical remission (per Adapted Mayo Score) and key secondary endpoints as an induction and maintenance treatment1,2.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Safety results were generally consistent with the known safety profile of risankizumab, with no new safety risks observed1,2 .
The results of the trading session contributed to over 3418955 shares changing hands. Over the past one week, the price volatility of AbbVie Inc. stands at 1.33% while the volatility over the past one month is 1.44%.
The market cap for ABBV stock reached $260.40 billion, with 1.77 billion shares outstanding and 1.76 billion shares in the current float. Compared to the average trading volume of 5.63M shares, ABBV reached a trading volume of 3418955 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about AbbVie Inc. [ABBV]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABBV shares is $169.14 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABBV stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
William Blair have made an estimate for AbbVie Inc. shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on July 25, 2023.
The Average True Range (ATR) for AbbVie Inc. is set at 2.25, with the Price to Sales ratio for ABBV stock in the period of the last 12 months amounting to 4.65. The Price to Book ratio for the last quarter was 20.27, with the Price to Cash per share for the same quarter was set at 4.97. Price to Free Cash Flow for ABBV in the course of the last twelve months was 10.50 with Quick ratio for the last quarter at 0.80.
How has ABBV stock performed recently?
AbbVie Inc. [ABBV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.44. With this latest performance, ABBV shares dropped by -1.33% in over the last four-week period, additionally sinking by -4.10% over the last 6 months – not to mention a rise of 8.24% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABBV stock in for the last two-week period is set at 51.24, with the RSI for the last a single of trading hit 44.96, and the three-weeks RSI is set at 53.35 for AbbVie Inc. [ABBV]. The present Moving Average for the last 50 days of trading for this stock 142.92, while it was recorded at 147.08 for the last single week of trading, and 150.52 for the last 200 days.
AbbVie Inc. [ABBV]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and AbbVie Inc. [ABBV] shares currently have an operating margin of +38.93 and a Gross Margin at +71.67. AbbVie Inc.’s Net Margin is presently recorded at +20.29.
Return on Total Capital for ABBV is now 25.91, given the latest momentum, and Return on Invested Capital for the company is 14.97. Return on Equity for this stock inclined to 72.15, with Return on Assets sitting at 8.26. When it comes to the capital structure of this company, AbbVie Inc. [ABBV] has a Total Debt to Total Equity ratio set at 372.04. Additionally, ABBV Total Debt to Total Capital is recorded at 78.82, with Total Debt to Total Assets ending up at 46.25. Long-Term Debt to Equity for the company is recorded at 347.10, with the Long-Term Debt to Total Capital now at 73.53.
Reflecting on the efficiency of the workforce at the company, AbbVie Inc. [ABBV] managed to generate an average of $235,640 per employee. Receivables Turnover for the company is 5.47 with a Total Asset Turnover recorded at a value of 0.41.AbbVie Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 0.90.
Earnings analysis for AbbVie Inc. [ABBV]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABBV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AbbVie Inc. go to -4.13%.
Insider trade positions for AbbVie Inc. [ABBV]
The top three institutional holders of ABBV stocks are: VANGUARD GROUP INC with ownership of 1.31 billion shares, which is approximately 8.2089%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $170.67 trillion in ABBV stocks shares; and BERKSHIRE HATHAWAY INC, currently with $150.98 trillion in ABBV stock with ownership which is approximately 5.7381%.
